Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

Lasagna, Angioletta; Bergami, Federica; Lilleri, Daniele; Percivalle, Elena; Quaccini, Mattia; Alessio, Niccolò Leandro; Comolli, Giuditta; Sarasini, Antonella; Sammartino, José Camilla; Ferrari, Alessandro; Arena, Francesca; Secondino, Simona; Cicognini, Daniela; Schiavo, Roberta; Cascio, Giuliana Lo; Cavanna, Luigi; Baldanti, Fausto; Pedrazzoli, Paolo; Cassaniti, Irene

doi:10.1016/j.esmoop.2022.100458

Cited by 20 publications

(32 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Published data on T-cell response has so far been scarce and partly contradictory. Whereas Lasagna and colleagues ( 36 ) reported higher T-cell responses in patients treated with immunotherapy, a recent study by Corradini et al ( 37 ) documented comparable T-cell responses across different subgroups of fragile and immune-compromised patients.…”

Section: Discussionmentioning

confidence: 96%

“…higher humoral response after booster, 88.5% with seroconversion Lasagna A, et al EMSO Open. ( 36 ) BNT162b2 21 days yes yes yes 142 (humoral analysis), 77 (cellular analysis), 10 (neutral Ab analysis) All receiving chemo and/or IO 0 0 Sign. higher humoral response after booster, no effect of age or treatment type on humoral response; significant increase of cellular response after booster, T-cell non-responders sign.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

Fischer

Demmer-Steingruber

et al. 2022

ESMO Open

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

Fischer

Demmer-Steingruber

et al. 2022

ESMO Open

View full text Add to dashboard Cite

“…According to our protocol 5 , Anti-S IgG levels were determined with a Trimeric assay (Liaison, Diasorin, Saluggia, Italy) and the results were given as BAU/ml (positive results >33.8 BAU/ml). The neutralizing antibody (NT Ab) titers against the wild type (WT) strain (dark grey) and B.1.1.529 (omicron) variant strain (light grey) were measured as previously reported 6 , we defined the results as positive when NT Ab was ≥ 1:10. T-cell response against Spike protein was detected by IFNγ release assay (IGRA from Euroimmun, Lübeck, Germany) 6 .…”

mentioning

confidence: 99%

“…The neutralizing antibody (NT Ab) titers against the wild type (WT) strain (dark grey) and B.1.1.529 (omicron) variant strain (light grey) were measured as previously reported 6 , we defined the results as positive when NT Ab was ≥ 1:10. T-cell response against Spike protein was detected by IFNγ release assay (IGRA from Euroimmun, Lübeck, Germany) 6 . A positive T-cell response was defined as >200 mIU/ml while the results ranging from 100 to 200 mIU/ml were defined as borderline.…”

mentioning

confidence: 99%

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment

Lasagna¹,

Bergami²,

Lilleri³

et al. 2022

Annals of Oncology

Self Cite

View full text Add to dashboard Cite

“…These studies show a low incidence of severe adverse drug reactions (ADRs) most of them being pain at the site of injection, fatigue, myalgia and fever. [13][14][15][16] In this study we describe and analyse the safety profile of the three-dose schedule mRNA-1273 vaccine in a cohort of solid cancer patients under active cancer treatment in a tertiary hospital in Madrid, Spain.…”

Section: Introductionmentioning

confidence: 99%

Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain

et al. 2022

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or were underrepresented. Methods: The objective of this study is to evaluate the safety profile of the mRNA-1273 vaccine across cancer patients and its relationship to patients’ demographics. We selected from our records all 18-years or older solid cancer patients under active treatment vaccinated with the complete three-dose schedule mRNA-1273 vaccine whose adverse drug reactions (ADRs) after each dose were recorded. Medical records were reviewed retrospectively to collect data between April 19, 2021, and December 31, 2021. Patients with documented previous infection by SARS-Cov-2 were excluded. Results: A total of 93 patients met the inclusion criteria. Local ADRs were reported more frequently after the first and second dose than after the third (41.9%, 43% and 31.1% of the patients respectively), while systemic ADRs followed the opposite pattern (16.1%, 34.4% and 52.6% of the patients respectively). We found a statistically significant association between sex and systemic adverse reactions after the third dose, p < 0.001 and between systemic adverse reactions after the second dose and systemic adverse reactions after the third dose, p = 0.001 A significant linear trend, p = 0.012, with a higher Eastern Cooperative Oncology Group (ECOG) score associated with a lower proportion of patients suffering from systemic side effects was found. Women had 5.79 times higher odds to exhibit systemic ADRs after the third dose (p=0.01) compared to males. Increasing age was associated with a decreased likelihood of exhibiting ADRs (p=0.016). Conclusion: The mRNA-1273 vaccine shows a tolerable safety profile. The likelihood of ADRs appears to be associated with gender and age. Its association with ECOG scores is less evident. Further studies are needed to elucidate this data in cancer patients.

show abstract

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

Cited by 20 publications

References 27 publications

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment

Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain

Contact Info

Product

Resources

About